Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Physician Practice Variability in the Use of Extended-Fraction Radiation Therapy for Bone Metastases: Are We Choosing Wisely?
Wang, Peiqi , Sedhom, Ramy , Chino, Fumiko , Waddle, Mark R. , Johnson, David H. , Sanford, Nina N. , Narang, Amol , Alcorn, Sara R. , Makary, Martin A. , Gupta, Arjun , Miller, Robert C.

Mayo Clinic

JCO Oncology Practice | April 13, 2020 | Volume: 16 | Issue: 8 | Pages: e758-e769

10.1200/jop.19.00633 | PMID 32282264 Get It

PURPOSE: Routine use of extended-fraction (> 10 fractions) radiation therapy (RT) for palliation of bone metastases is recognized as a low-value intervention by the American Society for Radiation Oncology. We examined contemporary practice patterns of, and physician characteristics associated with extended-fraction RT use. MATERIALS AND METHODS: We conducted a retrospective cohort study using Medicare fee-for-service data. We included patients who underwent 2- or 3-dimensional external-beam RT for bone metastases between January 1, 2016, and December 31, 2018. Physicians treating > 10 patients over the study period were analyzed for their individual practice. Hierarchic logistic regression modeling was used to identify patient- and physician-level factors associated with extended-fraction RT use. RESULTS: A total of 12,221 patients (median age, 75.6 years; 40.9% women, 87.6% white) were included. The rate of extended-fraction RT was 23.4%. A total of 1,432 physicians treated any patient. Among the 382 physicians treating > 10 patients, 127 (33.2%) used extended-fraction RT > 30% (consensus threshold). Physician factors associated with decreased odds of extended-fraction RT were years since medical school graduation (≤ 10 years and 11-20 years v ≥ 31 years: adjusted odds ratio [aOR], 0.32 [95% CI, 0.20 to 0.51] and 0.64 [95% CI, 0.44 to 0.93]) and practicing in the Northeast or Midwest versus the South (aOR, 0.36 [95% CI, 0.22 to 0.58] and 0.48 [95% CI, 0.31 to 0.74]). Physicians treating > 20 patients ( v 11-14 patients) over the study period had increased odds of delivering extended-fraction RT (aOR, 1.53 [95% CI, 1.10 to 2.12]). CONCLUSION: In this study, almost one fourth of patients received extended-fraction RT, and one third of physicians had an extended-fraction RT use rate of > 30%. Personalized feedback of performance data, clinical pathways and peer review, and updated reimbursement models are potential mechanisms to address this low-value care.
Time event ontology (TEO): to support semantic representation and reasoning of complex temporal relations of clinical events
Li, Fang , Du, Jingcheng , He, Yongqun , Song, Hsing-Yi , Madkour, Mohcine, Luo, Yi , Chen, Henry W. , Wang, Liwei , Xu, Hua , Tao, Cui , Liu, Sijia , Tao, Cui , He, Yongqun , Li, Fang , Madkour, Mohcine, Rao, Guozheng , Xiang, Yang , Liu, Hongfang

Mayo Clinic

Journal of the American Medical Informatics Association | April 13, 2020 | Volume: 27 | Issue: 7 | Pages: 1046-1056

10.1093/jamia/ocaa058 | PMID 32626903 Get It

Abstract Objective The goal of this study is to develop a robust Time Event Ontology (TEO), which can formally represent and reason both structured and unstructured temporal information. Materials and Methods Using our previous Clinical Narrative Temporal Relation Ontology 1.0 and 2.0 as a starting point, we redesigned concept primitives (clinical events and temporal expressions) and enriched temporal relations. Specifically, 2 sets of temporal relations (Allen’s interval algebra and a novel suite of basic time relations) were used to specify qualitative temporal order relations, and a Temporal Relation Statement was designed to formalize quantitative temporal relations. Moreover, a variety of data properties were defined to represent diversified temporal expressions in clinical narratives. Results TEO has a rich set of classes and properties (object, data, and annotation). When evaluated with real electronic health record data from the Mayo Clinic, it could faithfully represent more than 95% of the temporal expressions. Its reasoning ability was further demonstrated on a sample drug adverse event report annotated with respect to TEO. The results showed that our Java-based TEO reasoner could answer a set of frequently asked time-related queries, demonstrating that TEO has a strong capability of reasoning complex temporal relations. Conclusion TEO can support flexible temporal relation representation and reasoning. Our next step will be to apply TEO to the natural language processing field to facilitate automated temporal information annotation, extraction, and timeline reasoning to better support time-based clinical decision-making.
Clinical presentation and characteristics of pelvic floor myofascial pain in patients presenting with constipation
Liu, Andy , Chedid, Victor , Vijayvargiya, Priya , Camilleri, Michael , Wang, Xiao J, Camilleri, M , Chedid, Victor G , Wang, Xiao J.

Mayo Clinic

Neurogastroenterology & Motility | April 13, 2020 | Volume: 32 | Issue: 7 | Pages: No page available

10.1111/nmo.13845 | PMID 32281205 Get It

AbstractBackgroundPatients with pelvic floor myofascial pain (PFMP) have puborectalis tenderness on digital rectal examination (DRE). Little is known about its significance to anorectal function in patients presenting with constipation.AimTo characterize demographics, clinical characteristics, findings on anorectal manometry (ARM), diagnosis of rectal evacuation disorder (RED), colonic transit [normal (NTC) or slow (STC)], and imaging in constipated patients with PFMP and compare these features to constipation without PFMP.MethodsWe performed an electronic medical records review of patients with constipation evaluated by a single gastroenterologist between January 2008 and February 2019. Patients with PFMP were compared to controls with constipation but without PFMP (1:2 ratio).Key ResultsA total of 98 PFMP cases and 196 controls were identified. Constipated patients with PFMP were more likely to have RED [OR 7.59 (3.82‐15.09), P < .01]; controls were more likely to have either NTC [OR 4.25 (1.45‐12.42), P < .01] or STC [OR 3.57 (1.45‐8.78), P < .01]. RED in patients with PFMP is supported by comparison to controls: On DRE, they had increased resting tone [OR 2.25 (1.33‐3.83), P < .01] and paradoxical contraction of the puborectalis upon simulated evacuation [OR 3.41 (1.94‐6.00), P < .01]; on ARM, they had higher maximum resting pressure (102.9 mmHg vs 90.7 mmHg, P < .01) and lower rectoanal pressure gradient (−39.4 mmHg vs −24.7 mmHg, P < .01).Conclusions/InferencesIn constipated patients, PFMP is highly associated with RED. Its presence provides a valuable clue regarding the etiology of a patient's constipation; it should be assessed in all patients with constipation and should also be an additional target for management.
Time‐Restricted Eating Effects on Body Composition and Metabolic Measures in Humans who are Overweight: A Feasibility Study
Chow, Lisa S. , Alvear, Alison , Fleischer, Jason , Thor, Honoree, Dietsche, Katrina , Wang, Qi , Esch, Nicholas, Malaeb, Samar , Harindhanavudhi, Tasma , Panda, Satchidananda , Mashek, Douglas G. , Manoogian, Emily N. C. , Fleischer, Jason , Hodges, James S. , Nair, K. Sreekumaran

Mayo Clinic

Obesity | April 9, 2020 | Volume: 28 | Issue: 5 | Pages: 860-869

10.1002/oby.22756 | PMID 32270927 Get It

Objective In contrast to intentionally restricting energy intake, restricting the eating window may be an option for treating obesity. By comparing time‐restricted eating (TRE) with an unrestricted (non‐TRE) control, it was hypothesized that TRE facilitates weight loss, alters body composition, and improves metabolic measures. Methods Participants (17 women and 3 men; mean [SD]: 45.5 [12.1] years; BMI 34.1 [7.5] kg/m 2 ) with a prolonged eating window (15.4 [0.9] hours) were randomized to TRE ( n = 11: 8‐hour window, unrestricted eating within window) versus non‐TRE ( n = 9: unrestricted eating) for 12 weeks. Weight, body composition (dual x‐ray absorptiometry), lipids, blood pressure, 2‐hour oral glucose tolerance, 2‐week continuous glucose monitoring, and 2‐week physical activity (actigraphy assessed) were measured during the pre‐ and end‐intervention periods. Results The TRE group significantly reduced the eating window (end‐intervention window: 9.9 [2.0] hours) compared with the non‐TRE group (end‐intervention window: 15.1 [1.1] hours) ( P < 0.01). Compared with non‐TRE, TRE decreased the number of eating occasions, weight, lean mass, and visceral fat (all P ≤ 0.05). Compared with preintervention measures, the TRE group reduced the number of eating occasions (−21.9% [30.1%]) and reduced weight (−3.7% [1.8%]), fat mass (−4% [2.9%]), lean mass (−3.0% [2.7%]), and visceral fat (−11.1% [13.4%]) (all P ≤ 0.05). Physical activity and metabolic measures remained unchanged. Conclusions In the setting of a randomized trial, TRE presents a simplified view of food intake that reduces weight.
Cytologic grading of primary malignant salivary gland tumors: A blinded review by an international panel
Johnson, Daniel N. , Önenerk, Mine , Krane, Jeffrey F. , Barkan, Güliz A. , Bongiovanni, Massimo , Callegari, Fabiano , Canberk, Şule , Dixon, Glen R., Field, Andrew , Griffith, Christopher , Jhala, Nirag, Lin, Oscar , Perez‐Machado, Miguel , Pusztaszeri, Marc , Wang, He , Zarka, Matthew A., Rossi, Esther Diana , Barkan, Güliz , Bongiovanni, Massimo , Griffith, Christopher C , Jiang, Sara , Lin, Oscar , Maleki, Zahra , Pusztaszeri, Marc , Faquin, William C , Field, Andrew , Rossi, Esther Diana , Baloch, Zubair , Kurtycz, Daniel F. I. , Layfield, Lester James , Maleki, Zahra , Vielh, Philippe R.

Mayo Clinic

Cancer Cytopathology | April 8, 2020 | Volume: 128 | Issue: 6 | Pages: 392-402

10.1002/cncy.22271 | PMID 32267606 Get It

BackgroundFine needle aspiration (FNA) is commonly used for the preoperative evaluation of salivary gland tumors. Tumor grade is a key factor influencing clinical management of salivary gland carcinomas (SGCs). To assess the ability to grade nonbasaloid SGCs in FNA specimens, an international panel of cytopathologists convened to review and score SGC cases.MethodsThe study cohort included 61 cases of primary SGC from the pathology archives of 3 tertiary medical centers. Cases from 2005 to 2016 were selected, scanned, and digitized. Nineteen cytopathologists blinded to the histologic diagnosis reviewed the digitized cytology slides and graded them as low, high, or indeterminate. The panelists' results were then compared to the tumor grades based on histopathologic examination of the corresponding resection specimens.ResultsAll but 2 of the 19 (89.5%) expert panelists review more than 20 salivary gland FNAs per year; 16 (84.2%) of the panelists work at academic medical centers, and 13 (68.4%) have more than 10 years' experience. Participants had an overall accuracy of 89.4% in the grading of SGC cases, with 90.2% and 88.3% for low‐ and high‐grade SGC, respectively. Acinic cell carcinoma and mucoepidermoid carcinoma had the highest degree of accuracy, while epithelial‐myoepithelial carcinoma and salivary duct carcinoma had the lowest degree of accuracy. As expected, the intermediate‐grade SGC cases showed the greatest variability (high‐grade, 42.1%; low‐grade, 37.5%, indeterminate, 20.4%).ConclusionThis study confirms the high accuracy of cytomorphologic grading of primary SGC by FNA as low‐ or high‐grade. However, caution should be exercised when a grade cannot be confidently assigned.
Prognostic significance of patent foramen ovale in anticoagulated patients with atrial fibrillation
Melduni, Rowlens M. , Asirvatham, Samuel J. , Patlolla, Sri Harsha , Greene, Eddie L., Oh, Jae K. , Lee, Hon-Chi, Wang, Zhenzhen , Asirvatham, Samuel J , Melduni, Rowlens , Harsha Patlolla, Sri , Wysokiński, Waldemar E. , Gersh, Bernard J.

Mayo Clinic

Open Heart | April 7, 2020 | Volume: 7 | Issue: 1 | Pages: e001229

10.1136/openhrt-2019-001229 | PMID 32518658 Get It

Objective Previous studies have postulated a causal role of patent foramen ovale (PFO) in the aetiology of embolic stroke in the general population. We hypothesised that the presence of concomitant PFO and atrial fibrillation (AF) will add incremental risk of ischaemic stroke to that linked to AF alone. Methods We analysed data on 3069 consecutive patients (mean age 69.4±12.2 years; 67.1% men) undergoing transoesophageal echocardiography-guided electrical cardioversion (ECV) for AF between May 2000 and March 2012. PFO was identified by colour Doppler and agitated saline contrast study. All patients were followed up after ECV for first documentation of ischaemic stroke. Outcomes were compared using Cox regression models. Results The prevalence of PFO was 20.0% and the shunt direction was left-to-right in the majority of patients (71.4%). Patients with PFO had a higher frequency of obstructive sleep apnoea (21.7% vs 17.1%, p=0.01) and higher mean peak left atrial appendage emptying velocity (38.3±21.8 vs 36.1±20.4 cm/s; p=0.04) compared with those without PFO. Otherwise, baseline characteristics were similar between groups. During a mean follow-up period of 7.3±4.6 years, 214 patients (7.0%) had ischaemic stroke. Multivariable analysis showed no significant association between PFO and ischaemic stroke (HR, 0.82 (95% CI 0.57 to 1.18)). PFO shunt direction was strongly associated with stroke: HR, 1.91 (95% CI 1.16 to 3.16) for right-to-left shunt and HR, 0.58 (95% CI 0.36 to 0.93) for left-to-right shunt. Conclusions The presence of concurrent PFO in this largely anticoagulated group of patients with AF was not associated with increased risk of ischaemic stroke.
Cardiorenal syndrome: Multi‐organ dysfunction involving the heart, kidney and vasculature
Savira, Feby , Magaye, Ruth , Liew, Danny , Reid, Christopher M. , Kelly, Darren J. , Kompa, Andrew R. , Sangaralingham, S. Jeson , Burnett, John C. , Kaye, David M. , Wang, Bing H. , Kaye, David M , Sangaralingham, S. Jeson

Mayo Clinic

British Journal of Pharmacology | April 6, 2020 | Volume: 177 | Issue: 13 | Pages: 2906-2922

10.1111/bph.15065 | PMID 32250449 Get It

Cardiorenal syndrome (CRS) is a multi‐organ disease, encompassing heart, kidney and vascular system dysfunction. CRS is a worldwide problem, with high morbidity, mortality, and inflicts a significant burden on the health care system. The pathophysiology is complex, involving interactions between neurohormones, inflammatory processes, oxidative stress and metabolic derangements. Therapies remain inadequate, mainly comprising symptomatic care with minimal prospect of full recovery. Challenges include limiting the contradictory effects of multi‐organ targeted drug prescriptions and continuous monitoring of volume overload. Novel strategies such as multi‐organ transplantation and innovative dialysis modalities have been considered but lack evidence in the CRS context. The adjunct use of pharmaceuticals targeting alternative pathways showing positive results in preclinical models also warrants further validation in the clinic. In recent years, studies have identified the involvement of gut dysbiosis, uraemic toxin accumulation, sphingolipid imbalance and other unconventional contributors, which has encouraged a shift in the paradigm of CRS therapy.
Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
Zhang, Kai , Hong, Xiaohua , Song, Zhengbo , Xu, Yu , Li, Chengcheng , Wang, Guoqiang , Zhao, Xiaochen , Zhao, Zhengyi, Zhao, Jing , Huang, Mengli , Huang, Depei , Qi, Chuang , Gao, Chan , Cai, Shangli , Gu, Feifei, Hu, Yue , Wang, Wenxian , Liu, Li , Zhang, Yuzi , Xu, Chunwei , Liu, Li , Xu, Chunwei , Lou, Zhenkun

Mayo Clinic

Clinical Cancer Research | April 2, 2020 | Volume: 26 | Issue: 14 | Pages: 3649-3661

10.1158/1078-0432.ccr-19-3976 | PMID 32241817 Get It

Abstract Purpose: NOTCH signaling is associated with tumorigenesis, mutagenesis, and immune tolerance in non–small cell lung cancer (NSCLC), indicating its association with the clinical benefit of immune checkpoint inhibitors (ICI). We hypothesized that NOTCH mutation in NSCLC might be a robust predictor of immunotherapeutic efficacy. Experimental Design: Multiple-dimensional data including genomic, transcriptomic, and clinical data from cohorts of NSCLC internal and public cohorts involving immunotherapeutic patients were analyzed. Polymorphism Phenotyping v2 (PolyPhen-2) system was performed to determine deleterious NOTCH mutation (del-NOTCHmut). Further investigation on molecular mechanism was performed in The Cancer Genome Atlas (TCGA) data via CIBERSORT and gene set enrichment analysis. Results: Our 3DMed cohort (n = 58) and other four cohorts (Rizvi, POPLAR/OAK, Van Allen, and MSKCC; n = 1,499) uncovered marked correlation between NOTCH1/2/3 mutation and better ICI outcomes in EGFR/ALKWT population, including objective response rate (2.20-fold, P = 0.001), progression-free survival [HR, 0.61; 95% confidence interval (CI), 0.46–0.81; P = 0.001], and overall survival (HR, 0.56; 95% CI, 0.32–0.96; P = 0.035). Del-NOTCHmut exhibited better predictive function than non-deleterious NOTCH mutation, potentially via greater transcription of genes related to DNA damage response and immune activation. Del-NOTCHmut was not linked with prognosis in TCGA cohorts and chemotherapeutic response, but was independently associated with immunotherapeutic benefit, delineating the predictive, but not prognostic, utility of del-NOTCHmut. Conclusions: This work distinguishes del-NOTCHmut as a potential predictor to favorable ICI response in NSCLC, highlighting the importance of genomic profiling in immunotherapy. More importantly, our results unravel a possibility of personalized combination immunotherapy as adding NOTCH inhibitor to ICI regimen in NSCLC, for the optimization of ICI treatment in clinical practice.
Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes
Jackson, Kyle R. , Bowring, Mary G. , Chen, Jennifer , Waldram, Madeleine M. , Benedetti, Enrico , Ratner, Lloyd E. , Kapur, Sandip , Pelletier, Ronald P. , Melcher, Marc L. , Singh, Pooja , Sudan, Debra L. , Posner, Marc P., El‐Amm, Jose M., Shapiro, Ron , Cooper, Matthew , Verbesey, Jennifer , Lipkowitz, George S. , Rees, Michael A. , Sankari, Bashir R., Gerber, David A. , Wellen, Jason R., Bozorgzadeh, Adel , Heher, Eliot , Weng, Francis L. , Helderman, J. Harold, Brayman, Kenneth L. , Oberholzer, José , Kozłowski, Tomasz , Covarrubias, Karina , Desai, Niraj M. , Massie, Allan B. , Segev, Dorry L. , Garonzik‐Wang, Jacqueline , Cooper, Matthew , Melcher, Marc L , Segev, Dorry L , Sudan, Debra L , Gerber, David A , Long, Jane J. , Motter, Jennifer D. , Orandi, Babak John , Montgomery, Robert A. , Stegall, Mark D. , Jordan, Stanley C. , Dunn, Ty B , Roberts, John P. , Marsh, Christopher L. , Gaber, A. Osama , Djamali, Arjang , Concepcion, Beatrice P.

Mayo Clinic

Transplantation | April 1, 2020 | Volume: 105 | Issue: 2 | Pages: 436-442

10.1097/tp.0000000000003254 | PMID 32235255 Get It

Background. Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown. Methods. We sought to quantify center-level variation in mortality and graft loss following ILDKT using a 25-center cohort of 1358 ILDKT recipients with linkage to Scientific Registry of Transplant Recipients for accurate outcome ascertainment. We used multilevel Cox regression with shared frailty to determine the variation in post-ILDKT outcomes attributable to between-center differences and to identify any center-level characteristics associated with improved post-ILDKT outcomes. Results. After adjusting for patient-level characteristics, only 6 centers (24%) had lower mortality and 1 (4%) had higher mortality than average. Similarly, only 5 centers (20%) had higher graft loss and 2 had lower graft loss than average. Only 4.7% of the differences in mortality (P < 0.01) and 4.4% of the differences in graft loss (P < 0.01) were attributable to between-center variation. These translated to a median hazard ratio of 1.36 for mortality and 1.34 of graft loss for similar candidates at different centers. Post-ILDKT outcomes were not associated with the following center-level characteristics: ILDKT volume and transplanting a higher proportion of highly sensitized, prior transplant, preemptive, or minority candidates. Conclusions. Unlike most aspects of transplantation in which center-level variation and volume impact outcomes, we did not find substantial evidence for this in ILDKT. Our findings support the continued practice of ILDKT across these diverse centers.
Lnc-M2 controls M2 macrophage differentiation via the PKA/CREB pathway
Li, Hanzhao , Ding, Tengteng , Li, Jinbang , Zhang, Yuanbin , Wang, Jianguo , Xu, Yang , Chong, Tuotuo, Long, Yufei , Li, Xin , Chen, Yuxiang , Li, Hanzhao, Wang, Jianguo, Lyu, Xiaoming , Gao, Fei

Mayo Clinic

No container title available | April 1, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.158575924.40440874 Get It

LncRNAs play an indispensable role in the process of M1 macrophage via regulating the development of macrophages and their responses to bacterial pathogens and viral infections. However, there are few studies on the lncRNA-mediated functions and regulatory mechanisms of M2 macrophage polarization. In this study, we found a number of differentially expressed lncRNAs between human monocyte derived M0 and M2 macrophages according to array analysis and qRT-PCR validation. The lncRNA RP11-389C8.2 (we named lnc-M2 in this study) was observed to be highly expressed in M2 macrophages. In Situ Localization and Quantification Analysis showed that lnc-M2 was expressed in the nucleus and cytosolic compartments of M2 macrophages. Notably, lnc-M2 knockdown enhanced the phagocytic ability of M2 macrophages. Ulteriorly, the results of RNA-Protein interaction experiments indicated that protein kinase A (PKA) was a lnc-M2 associated RNA-binding protein (RBP). Western blot showed that p-CREB, a well-known key downstream transcription factor of PKA, was lowly phosphorylated in lnc-M2-silencing M2 macrophages. Furthermore, we found that transcriptional factor STAT3 promoted lnc-M2 transcription along with the up-regulation of epigenetic histone modification markers at the lnc-M2 promoter locus, indicating that STAT3 activated lnc-M2 and eventually facilitated the process of M2 macrophage differentiation via the PKA/CREB pathway. Collectively, our date provide evidence that the transcription factor STAT3 can promote the transcription of lnc-M2 and facilitated the process of M2 macrophage differentiation via the PKA/CREB pathway. This study highlights a novel mechanism underlying the M2 macrophage differentiation.